- Home
- GMAB vs APTV Comparison
GMAB vs APTV Comparison
Compare GMAB & APTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- APTV
- Stock Information
- Founded
- GMAB 1999
- APTV 2011
- Country
- GMAB Denmark
- APTV Switzerland
- Employees
- GMAB N/A
- APTV N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- APTV Auto Parts:O.E.M.
- Sector
- GMAB Health Care
- APTV Consumer Discretionary
- Exchange
- GMAB Nasdaq
- APTV Nasdaq
- Market Cap
- GMAB 12.1B
- APTV 14.1B
- IPO Year
- GMAB N/A
- APTV 1999
- Fundamental
- Price
- GMAB $22.34
- APTV $66.67
- Analyst Decision
- GMAB Buy
- APTV Buy
- Analyst Count
- GMAB 9
- APTV 19
- Target Price
- GMAB $40.71
- APTV $84.71
- AVG Volume (30 Days)
- GMAB 1.9M
- APTV 3.2M
- Earning Date
- GMAB 02-12-2025
- APTV 02-06-2025
- Dividend Yield
- GMAB N/A
- APTV N/A
- EPS Growth
- GMAB 83.82
- APTV N/A
- EPS
- GMAB 16.85
- APTV 6.96
- Revenue
- GMAB $2,988,286,182.00
- APTV $19,713,000,000.00
- Revenue This Year
- GMAB $18.78
- APTV $3.28
- Revenue Next Year
- GMAB $14.98
- APTV $5.90
- P/E Ratio
- GMAB $13.00
- APTV $9.58
- Revenue Growth
- GMAB 30.67
- APTV N/A
- 52 Week Low
- GMAB $18.64
- APTV $51.47
- 52 Week High
- GMAB $31.88
- APTV $85.56
- Technical
- Relative Strength Index (RSI)
- GMAB 65.39
- APTV 64.93
- Support Level
- GMAB $18.74
- APTV $56.22
- Resistance Level
- GMAB $22.55
- APTV $67.40
- Average True Range (ATR)
- GMAB 0.46
- APTV 1.89
- MACD
- GMAB 0.39
- APTV 0.25
- Stochastic Oscillator
- GMAB 94.64
- APTV 87.40
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About APTV Aptiv PLC
Aptiv Holdings Ltd, formerly Aptiv PLC signal and power solutions segment supplies components and systems that make up a vehicle's electrical system, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, driver-assist technologies, and displays, as well as the development of software for these systems.